BIOMAT Database Logo BIOMAT Database Logo

Predictors of HIV seropositivity in Newark and Jersey City i.v. drug users not currently enrolled in treatment. 1990

M Y Iguchi, and M Rosen, and H Musikoff, and H Kushner, and J French, and R Baxter, and V Lidz, and J J Platt, and C Grant
University of Medicine & Dentistry of New Jersey, School of Osteopathic Medicine, Camden 08103.

UI MeSH Term Description Entries
D008297 Male Males
D009515 New Jersey State bounded on the north by New York and Pennsylvania, on the east by New York and the Atlantic Ocean, on the south by Delaware Bay, and on the west by Pennsylvania.
D012044 Regression Analysis Procedures for finding the mathematical function which best describes the relationship between a dependent variable and one or more independent variables. In linear regression (see LINEAR MODELS) the relationship is constrained to be a straight line and LEAST-SQUARES ANALYSIS is used to determine the best fit. In logistic regression (see LOGISTIC MODELS) the dependent variable is qualitative rather than continuously variable and LIKELIHOOD FUNCTIONS are used to find the best relationship. In multiple regression, the dependent variable is considered to depend on more than a single independent variable. Regression Diagnostics,Statistical Regression,Analysis, Regression,Analyses, Regression,Diagnostics, Regression,Regression Analyses,Regression, Statistical,Regressions, Statistical,Statistical Regressions
D005260 Female Females
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015819 Substance Abuse, Intravenous Abuse, overuse, or misuse of a substance by its injection into a vein. Drug Abuse, Intravenous,Drug Abuse, Parenteral,Intravenous Drug Abuse,Intravenous Substance Abuse,Parenteral Drug Abuse

Related Publications

M Y Iguchi, and M Rosen, and H Musikoff, and H Kushner, and J French, and R Baxter, and V Lidz, and J J Platt, and C Grant
HIV seropositivity in i.v. drug users in Ohio.
June 1988, American journal of public health,
M Y Iguchi, and M Rosen, and H Musikoff, and H Kushner, and J French, and R Baxter, and V Lidz, and J J Platt, and C Grant
HIV risk-taking behaviour among injecting drug users currently, previously and never enrolled in methadone treatment.
April 1995, Addiction (Abingdon, England),
M Y Iguchi, and M Rosen, and H Musikoff, and H Kushner, and J French, and R Baxter, and V Lidz, and J J Platt, and C Grant
Hopelessness in i.v. drug users not in treatment and seeking HIV testing and counselling.
January 1994, Drug and alcohol dependence,
M Y Iguchi, and M Rosen, and H Musikoff, and H Kushner, and J French, and R Baxter, and V Lidz, and J J Platt, and C Grant
HIV seropositivity in community-recruited and drug treatment samples of injecting drug users.
January 1992, AIDS (London, England),
M Y Iguchi, and M Rosen, and H Musikoff, and H Kushner, and J French, and R Baxter, and V Lidz, and J J Platt, and C Grant
Correlates of HIV seropositivity and HIV testing among out-of-treatment drug users.
August 1998, The American journal of drug and alcohol abuse,
M Y Iguchi, and M Rosen, and H Musikoff, and H Kushner, and J French, and R Baxter, and V Lidz, and J J Platt, and C Grant
Risk factors for HIV seropositivity in a sample of drug users in drug treatment in Ho Chi Minh City, Vietnam.
March 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
M Y Iguchi, and M Rosen, and H Musikoff, and H Kushner, and J French, and R Baxter, and V Lidz, and J J Platt, and C Grant
Drug use and HIV risk-taking behaviour among injecting drug users not currently in treatment in Sydney, Australia.
January 1994, Drug and alcohol dependence,
M Y Iguchi, and M Rosen, and H Musikoff, and H Kushner, and J French, and R Baxter, and V Lidz, and J J Platt, and C Grant
Prevention of HIV infection in i.v. drug users.
January 1988, Image--the journal of nursing scholarship,
M Y Iguchi, and M Rosen, and H Musikoff, and H Kushner, and J French, and R Baxter, and V Lidz, and J J Platt, and C Grant
Drug treatment and HIV seropositivity.
March 1988, New York state journal of medicine,
M Y Iguchi, and M Rosen, and H Musikoff, and H Kushner, and J French, and R Baxter, and V Lidz, and J J Platt, and C Grant
[Malaria in intravenous drug users associated with HIV seropositivity].
February 1991, Revista de saude publica,
Copied contents to your clipboard!